Optimal Cardiopulmonary Bypass and Anticoagulation Management Strategies in Obese Patients Undergoing Cardiac Surgery
Recruiting now NCT03302195
Run by Laval University · for 18 and older · All sexes
What this study is about
Standard Heparin management, based on total body weight, is not well established for obese patients undergoing cardiac surgery with cardiopulmonary bypass (CPB). The purpose of this study is to assess the safety and efficacy of using lean body mass (LBM) to determine pump flow rate and/or Heparin dosage in obese patients undergoing CPB.
Who can join (things the study team will check)
✅ You may be able to join if…
- Obese patients (BMI ≥ 30kg/m2)
- Planned cardiac surgery
- Age ≥ 18 years
🚫 You may not be able to join if…
- Permanent pacemaker
- Known intolerance to protamine
- Known or suspected allergy to the used antifibrinolytic agent
- Refusal to receive blood products
- Planned off pump coronary artery bypass
- Planned peri-operative use of desmopressin
- Known Heparin-induced thrombocytopenia
- Known deficiency in protein C, protein S, antithrombin or homozygous factor V Leiden
- Known congenital bleeding disorders
- Current endocarditis
- Planned hypothermic circulatory arrest (<28C)
- Two or more cardiac surgery procedures
- Emergency cardiac surgery procedures (medically required within 24hours of presenting with acute symptoms)
- Planned CPB priming with red blood cells
- Any known autoimmune disease
- Any history of stroke or non-coronary thrombotic disorders including deep venous thrombosis and pulmonary embolism
- Significant (≥50%) carotid artery stenosis
- Patient dosed with low molecular weight Heparin less than 24h before surgery
- Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods
- Confirmed ST elevation myocardial infarction (STEMI) within 7 days
+ 10 more criteria — see the full checklist in the app.
Where this trial is running
- Hopital Laval, Québec, Quebec, Canada
Who to contact
Hugo Tremblay, Bachelor · 418-656-8711 · hugo.tremblay@criucpq.ulaval.ca
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT03302195.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.